We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Abaco Capital | LSE:ABA | London | Ordinary Share | GB00B3LXPB43 | ORD 0.001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.50 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jan 2020 to Jan 2025
TIDMOXP
RNS Number : 3192Y
Oxford Pharmascience Group PLC
04 December 2017
Oxford Pharmascience Group plc
("Oxford Pharmascience" or the "Company")
Subdivision of Capital
Oxford Pharmascience Group plc (AIM: OXP) announces that, as contemplated in the Circular to Shareholders issued by the Company on 10 November 2017 and pursuant to the resolutions passed at a general meeting of shareholders on 27 November 2017, the Company has completed a subdivision of its capital whereby each Existing Share of GBP0.001 has been subdivided and reclassified into 1 New Share of GBP0.00001 and 1 Participating Deferred Share of GBP0.00099 (the "Subdivision").
Following the Subdivision the issued share capital of the Company consists of 1,205,661,619 New Shares of GBP0.00001 each and 1,205,661,619 Participating Deferred Shares of GBP0.00099 each.
Following the Subdivision, each Existing Shareholder's holding shall remain unchanged therefore no new share certificates will be issued. The total voting rights in the Company also remains unchanged, with 1,205,661,619 New Shares in issue. This figure may be used by Shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
The Capital Reduction remains subject to the Court's approval and a further announcement in relation to this and the Demerger will be made in due course.
Unless otherwise indicated, capitalised terms in this announcement have the meaning given to them in the definitions appearing in the circular issued by the Company on 10 November 2017.
For further information please contact:
Oxford Pharmascience Group Plc ----------------------------- ----------------- Chris Hill, Chief Financial Officer +44 20 7554 5875 ----------------------------- ----------------- N+1 Singer (Nominated Adviser & Broker) ----------------------------- ----------------- Aubrey Powell/Jen Boorer +44 20 7496 3000 ----------------------------- -----------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCOKQDDQBDDDBK
(END) Dow Jones Newswires
December 04, 2017 09:14 ET (14:14 GMT)
1 Year Alba Chart |
1 Month Alba Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
